Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 24786 | 252 | 39.3 | 89% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | UCN 01 | Author keyword | 21 | 44% | 14% | 36 |
| 2 | 7 HYDROXYSTAUROSPORINE | Author keyword | 6 | 58% | 3% | 7 |
| 3 | 7 HYDROXYSTAUROSPORINE UCN 01 | Author keyword | 4 | 67% | 2% | 4 |
| 4 | STAUROSPORINE ANALOGS | Author keyword | 4 | 75% | 1% | 3 |
| 5 | CGP41251 | Author keyword | 3 | 100% | 1% | 3 |
| 6 | PKC412 | Author keyword | 2 | 27% | 3% | 8 |
| 7 | IN VITRO ANTIPROLIFERATION | Author keyword | 2 | 67% | 1% | 2 |
| 8 | CGP 41 251 | Author keyword | 1 | 38% | 1% | 3 |
| 9 | CAS 120685 11 2 | Author keyword | 1 | 100% | 1% | 2 |
| 10 | CYCLIN DEPENDENT KINASE MODULATOR | Author keyword | 1 | 100% | 1% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | UCN 01 | 21 | 44% | 14% | 36 | Search UCN+01 | Search UCN+01 |
| 2 | 7 HYDROXYSTAUROSPORINE | 6 | 58% | 3% | 7 | Search 7+HYDROXYSTAUROSPORINE | Search 7+HYDROXYSTAUROSPORINE |
| 3 | 7 HYDROXYSTAUROSPORINE UCN 01 | 4 | 67% | 2% | 4 | Search 7+HYDROXYSTAUROSPORINE+UCN+01 | Search 7+HYDROXYSTAUROSPORINE+UCN+01 |
| 4 | STAUROSPORINE ANALOGS | 4 | 75% | 1% | 3 | Search STAUROSPORINE+ANALOGS | Search STAUROSPORINE+ANALOGS |
| 5 | CGP41251 | 3 | 100% | 1% | 3 | Search CGP41251 | Search CGP41251 |
| 6 | PKC412 | 2 | 27% | 3% | 8 | Search PKC412 | Search PKC412 |
| 7 | IN VITRO ANTIPROLIFERATION | 2 | 67% | 1% | 2 | Search IN+VITRO+ANTIPROLIFERATION | Search IN+VITRO+ANTIPROLIFERATION |
| 8 | CGP 41 251 | 1 | 38% | 1% | 3 | Search CGP+41+251 | Search CGP+41+251 |
| 9 | CAS 120685 11 2 | 1 | 100% | 1% | 2 | Search CAS+120685+11+2 | Search CAS+120685+11+2 |
| 10 | CYCLIN DEPENDENT KINASE MODULATOR | 1 | 100% | 1% | 2 | Search CYCLIN+DEPENDENT+KINASE+MODULATOR | Search CYCLIN+DEPENDENT+KINASE+MODULATOR |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | HUMAN EPIDERMOID CARCINOMA | 10 | 42% | 8% | 19 |
| 2 | LINE TSU PR1 | 9 | 83% | 2% | 5 |
| 3 | 7 HYDROXYSTAUROSPORINE UCN 01 | 9 | 29% | 10% | 25 |
| 4 | 7 HYDROXYSTAUROSPORINE | 5 | 37% | 4% | 11 |
| 5 | STAUROSPORINE DERIVATIVE CGP 41251 | 4 | 67% | 2% | 4 |
| 6 | UCN 01 | 4 | 16% | 10% | 25 |
| 7 | CGP 41 251 | 3 | 100% | 1% | 3 |
| 8 | P53 DEFECTIVE CELLS | 3 | 100% | 1% | 3 |
| 9 | UCN 01 7 HYDROXYSTAUROSPORINE | 3 | 38% | 2% | 6 |
| 10 | INHIBITOR UCN 01 | 2 | 67% | 1% | 2 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Review of UCN-01 development: A lesson in the importance of clinical pharmacology | 2005 | 70 | 25 | 84% |
| Staurosporine analogues - pharmacological toys or useful antitumour agents? | 2000 | 73 | 54 | 46% |
| Analogs of staurosporine: Potential anticancer drugs? | 1998 | 83 | 56 | 43% |
| Design of new anticancer therapies targeting cell cycle checkpoint pathways | 2001 | 39 | 56 | 16% |
| Pyrimidine and purine analogues, effects on cell cycle regulation and the role of cell cycle inhibitors to enhance their cytotoxicity | 2005 | 19 | 128 | 13% |
| Novel anticancer agents in clinical development | 2003 | 22 | 95 | 7% |
| Simultaneous interruption of signal transduction and cell cycle regulatory pathways: Implications for new approaches to the treatment of childhood leukemias | 2007 | 6 | 108 | 9% |
| Modulation of apoptosis signaling pathways and cell cycle regulation | 1999 | 51 | 53 | 6% |
| Molecular targeted therapy: A strategy of disillusions or optimism? | 2006 | 1 | 20 | 10% |
| Development of anti-cancer drugs based on molecular targeting and their application to brain tumor therapy | 2003 | 0 | 42 | 7% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | ORAL CELL BIOL GRP | 1 | 50% | 0.8% | 2 |
| 2 | HEMATOL ONCOLCANC MOL | 1 | 50% | 0.4% | 1 |
| 3 | LNMR | 1 | 50% | 0.4% | 1 |
| 4 | ONCOL CLIN ONCOL | 1 | 50% | 0.4% | 1 |
| 5 | ORAL PHARYNGEAL CANC BRANCHNIH | 1 | 50% | 0.4% | 1 |
| 6 | MED BRANCH CLIN SCI | 0 | 20% | 0.8% | 2 |
| 7 | CHILDRENS HOSP PITTSBURGH NEUROSURG | 0 | 33% | 0.4% | 1 |
| 8 | CLIN TRIALS UNITMED BRANCH | 0 | 33% | 0.4% | 1 |
| 9 | NEURO TUMOR CELL BIOL GRP | 0 | 17% | 0.8% | 2 |
| 10 | DRUG FORMULAT S | 0 | 15% | 0.8% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000228572 | REBECCAMYCIN//INDOLOCARBAZOLE//INDOLOCARBAZOLES |
| 2 | 0.0000199684 | FLAVOPIRIDOL//CELL CYCLE REGULAT GRP//ROSCOVITINE |
| 3 | 0.0000174756 | CHK1//RAD9//CLASPIN |
| 4 | 0.0000114083 | BRYOSTATIN 1//BRYOSTATIN//BRYOSTATINS |
| 5 | 0.0000095920 | ENZASTAURIN//C1 DOMAIN//INDOLACTAM |
| 6 | 0.0000091736 | BIOMARKERS BRANCH//CLONOGEN//COLORADO PARTY |
| 7 | 0.0000080921 | PROTEIN KINASE C ISOFORMS//PROTEIN KINASE C ISOZYMES//PROTEIN KINASE C SUBSPECIES |
| 8 | 0.0000079395 | IMMUNOCYTOFLUOROMETRY//CLASS II DR//CLIN STOMATOL 1 |
| 9 | 0.0000063940 | LASER SCANNING CYTOMETRY//MOL PATTERN RECOGNIT GRP//LASER SCANNING CYTOMETRY LSC |
| 10 | 0.0000056691 | G2 REPAIR//CHROMATID TYPE ABERRATIONS//G2 M OVERRIDE |